References
- Forsyth KD, Tan T, von König CW, et al. Recommendations to control pertussis prioritized relative to economies: a global pertussis initiative update. Vaccine. 2018;36:7270–7275.
- Muloiwa R, Kagina BM, Engel ME, et al. The burden of laboratory-confirmed pertussis in low- and middle-income countries since the inception of the expanded programme on immunisation (EPI) in 1974: a systematic review and meta-analysis. BMC Med. 2020;18:233.
- Kandeil W, Atanasov P, Avramioti D, et al. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. Expert Rev Vaccines. 2019;18:439–455.
- Gao H, Lau EHY, Cowling BJ. Waning immunity after receipt of pertussis, diphtheria, tetanus, and polio-related vaccines: a systematic review and meta-analysis. J Infect Dis. 2022;225:557–566.
- WHO. Pertussis reported cases and incidence. Cited 2023 Feb 15 Available from: https://immunizationdata.who.int/pages/incidence/PERTUSSIS.html?CODE=Global&YEAR=&ADVANCED_GROUPINGS=South%20Asia
- Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in Asia. Infect Dis Ther. 2021;10:1115–1140.
- Nicholson L, Adkins E, Karyanti MR, et al. What is the true burden of diphtheria, tetanus, pertussis and poliovirus in children aged 3–18 years in Asia? A systematic literature review. Int J Infect Dis. 2022;117:116–129.
- Chit A, Zivaripiran H, Shin T, et al. Acellular pertussis vaccines effectiveness over time: a systematic review, meta-analysis and modeling study. PLoS One. 2018;13:e0197970.
- Cassimos DC, Effraimidou E, Medic S, et al. Vaccination programs for adults in Europe, 2019. Vaccines (Basel). 2020 Jan 20;8(1):34.
- Government of Cananda. Pertussis vaccine: Canadian immunization Schedule. Cited Mar 2021https://www.canada.ca/en/public-health/services/publications/healthyliving/canadian-immunization-guide-part-4-activevaccines/page-15-pertussis-vaccine.html
- Havers FP, Moro PL, Hunter P, et al. Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the advisory committee on immunization practices - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(3):77–83.
- European Centers for Disease Prevention and Control. Pertussis: recommended vaccinations. Cited Aug 2020. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=3&SelectedCountryIdByDisease=−1
- Lecce M, Perrone PM, Castaldi S. Tdap booster vaccination for adults: real-world adherence to current recommendations in Italy and evaluation of two alternative strategies. Int J Environ Res Public Health. 2022 Mar 29;19(7):4066.
- National Centre for Immunisation Research and Surveillance. Pertussis vaccines for Australians. December 2022 Fact sheet. Cited 2023 Feb 13. Available at https://ncirs.org.au/sites/default/files/2022-12/Pertussis%20fact%20sheet%20December%202022.pdf
- Fernandes EG, Rodrigues CCM, Sartori AMC, et al. Economic evaluation of adolescents and adults’ pertussis vaccination: a systematic review of current strategies. Hum Vaccin Immunother. 2019;15:14–27.
- WHO. Pertussis vaccines: WHO position paper, August 2015–Recommendations. Vaccine. 2016;34(12):1423–1425.
- Sharma H, Anil K, Parekh S, et al. A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults. Vaccine. 2021;39:882–885.
- Kadam L, Patel K, Gautam M, et al. Development and validation of magnetic bead pentaplex immunoassay for simultaneous quantification of murine serum IgG antibodies to acellular pertussis, diphtheria and tetanus antigens used in combination vaccines. Methods. 2019;158:33–43.
- ICH harmonised guideline: bioanalytical method validation M10. [Cited 2023 Feb 25]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf
- US FDA. Guidance for industry on bioanalytical method validation. [Cited 2023 Feb 25]. Available at https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
- van Gageldonk PG, van Schaijk FG, van der Klis FR, et al. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008;335(1–2):79–89.
- Rajam G, Carlone G, Kim E, et al. Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens. Biologicals. 2019;57:9–20.
- Itell HL, McGuire EP, Muresan P, et al. Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. Vaccine. 2018;36(37):5600–5608.
- World Health Organization Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines, Annex 4, WHO TRS No 979. Geneva: WHO; 2013.
- Cherry JD, Gornbein J, Heininger U, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16:1901–1906.
- Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907–1916.
- Rivera L, Schwarz TF, Kim KH, et al. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: a phase III, randomized study. Vaccine. 2018;36:4750–4758.
- McCormack PL. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization. Drugs. 2012;72:1765–1791.
- Asatryan A, Meyer N, Scherbakov M, et al. Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study. Hum Vaccin Immunother. 2021;17:723–730.